A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects

Trial Profile

A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Andexanet alfa (Primary) ; Apixaban; Edoxaban; Enoxaparin sodium; Rivaroxaban
  • Indications Haemorrhage
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 31 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 06 Sep 2017 Planned End Date changed from 31 Aug 2017 to 30 Sep 2017.
    • 06 Sep 2017 Planned primary completion date changed from 31 Aug 2017 to 30 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top